Impact of TP53 mutations on efficacy of PD-1 targeted immunotherapy in non-small cell lung cancer (NSCLC).Jennifer W. Carlisle, Taofeek K. Owonikoko, Chaejin Kim et al.|Journal of Clinical Oncology|2018Cited by 13